Phosphorylation by p38 mitogen-activated protein kinase promotes estrogen receptor α turnover and functional activity via the SCFskp2 proteasomal complex

Molecular and Cellular Biology

Volumn 32, Issue 10, 2012, Pages 1928-1943

  Bhatt, Shweta ^a   Xiao, Zhen ^b   Meng, Zhaojing ^b   Katzenellenbogen, Benita S ^c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; S PHASE KINASE ASSOCIATED PROTEIN 2; SERINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVITY; CELL CYCLE REGULATION; CELL PROLIFERATION; COMPLEX FORMATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOGENICITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 84861411190     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06561-11     Document Type: Article

References (59)

1. Aesoy R, et al. 2008. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol. Cancer Res. 6:1630-1638.
2. Alarid ET. 2006. Lives and times of nuclear receptors. Mol. Endocrinol. 20:1972-1981.
3. Atsriku C, et al. 2009. Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol. Cell. Proteomics 8:467-480.
4. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. 2004. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 428:190-193.
5. Bergamaschi A, Christensen BL, Katzenellenbogen BS. 2011. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3zeta, FOXM1, and a gene signature associated with mitosis. Breast Cancer Res. 13:R70.
6. Berry NB, Fan M, Nephew KP. 2008. Estrogen receptor-alpha hingeregion lysines 302 and 303 regulate receptor degradation by the proteasome. Mol. Endocrinol. 22:1535-1551.
7. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. 2005. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 26:331-345.
8. Byun B, Jung Y. 2008. Repression of transcriptional activity of estrogen receptor alpha by a Cullin3/SPOP ubiquitin E3 ligase complex. Mol. Cells 25:289-293.
9. Calvisi DF, et al. 2009. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 137:1816-1826.e10.
10. Cardozo T, Pagano M. 2004. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5:739-751.
11. Chang EC, et al. 2008. Estrogen receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol. Endocrinol. 22:1032-1043.
12. Chu I, et al. 2007. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J. Clin. Invest. 117:2205-2215.
13. Connor CE, et al. 2001. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res. 61:2917-2922.
14. Dauvois S, Danielian PS, White R, Parker MG. 1992. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 89:4037-4041.
15. Eakin CM, Maccoss MJ, Finney GL, Klevit RE. 2007. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 104:5794-5799.
16. Eckert RL, Mullick A, Rorke EA, Katzenellenbogen BS. 1984. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology 114:629-637.
17. Fan M, Park A, Nephew KP. 2005. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol. Endocrinol. 19:2901-2914.
18. Frasor J, et al. 2003. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574.
19. Gao D, et al. 2009. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat. Cell Biol. 11:397-408.
20. Gonzalez F, Delahodde A, Kodadek T, Johnston SA. 2002. Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 296: 548-550.
21. Gstaiger M, et al. 2001. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. U.S.A. 98:5043-5048.
22. Guardavaccaro D, Pagano M. 2006. Stabilizers and destabilizers controlling cell cycle oscillators. Mol. Cell 22:1-4.
23. Hershko DD. 2008. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 112:1415-1424.
24. Hu CD, Chinenov Y, Kerppola TK. 2002. Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol. Cell 9:789-798.
25. Huang CY, et al. 1998. Lipitoids-novel cationic lipids for cellular delivery of plasmid DNA in vitro. Chem. Biol. 5:345-354.
26. Ji P, et al. 2006. Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1. J. Biol. Chem. 281: 24058-24069.
27. Johnston SR, Martin LA, Leary A, Head J, Dowsett M. 2007. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J. Steroid Biochem. Mol. Biol. 106:180-186.
28. Jordan VC, O'Malley BW. 2007. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25:5815-5824.
29. Katzenellenbogen BS, Frasor J. 2004. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 31:28-38.
30. Kieser KJ, Kim DW, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. 2010. Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). J. Med. Chem. 53:3320-3329.
31. Laios I, et al. 2005. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J. Steroid Biochem. Mol. Biol. 94:347-359.
32. Lange CA, Shen T, Horwitz KB. 2000. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl. Acad. Sci. U.S.A. 97:1032-1037.
33. Lin HK, et al. 2009. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat. Cell Biol. 11:420-432.
34. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. 2000. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell 5:939-948.
35. Ma Y, et al. 2010. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol. Endocrinol. 24:76-90.
36. Madak-Erdogan Z, Lupien M, Stossi F, Brown M, Katzenellenbogen BS. 2011. Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol. Cell. Biol. 31:226-236.
37. McInerney EM, Weis KE, Sun J, Mosselman S, Katzenellenbogen BS. 1998. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 139:4513-4522.
38. Metivier R, et al. 2003. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115:751-763.
39. Monsma FJ, Jr, Katzenellenbogen BS, Miller MA, Ziegler YS, Katzenellenbogen JA. 1984. Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently-attaching antiestrogen. Endocrinology 115:143-153.
40. Montemurro F, Aglietta M, Del Mastro L. 2009. Aromatase inhibitors as adjuvant therapy for breast cancer. J. Clin. Oncol. 27:2566-2567.
41. Musgrove EA, Sutherland RL. 2009. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9:631-643.
42. Nakayama KI, Nakayama K. 2006. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6:369-381.
43. Nalepa G, Rolfe M, Harper JW. 2006. Drug discovery in the ubiquitinproteasome system. Nat. Rev. Drug Discov. 5:596-613.
44. Radke S, Pirkmaier A, Germain D. 2005. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene 24:3448-3458.
45. Ramamoorthy S, Nawaz Z. 2008. E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nucl. Recept. Signal. 6:e006.
46. Ravaioli A, et al. 2008. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in nodenegative early breast cancer. Ann. Oncol. 19:660-668.
47. Reed SI. 2008. Deathproof: new insights on the role of skp2 in tumorigenesis. Cancer Cell 13:88-89.
48. Reid G, et al. 2003. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 11:695-707.
49. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. 2007. Pathways to tamoxifen resistance. Cancer Lett. 256:1-24.
50. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852.
51. Shen T, Horwitz KB, Lange CA. 2001. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell. Biol. 21:6122-6131.
52. Signoretti S, et al. 2002. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110:633-641.
53. Stanisic V, Malovannaya A, Qin J, Lonard DM, O'Malley BW. 2009. OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity. J. Biol. Chem. 284:16135-16145.
54. Stossi F, Madak-Erdogan Z, Katzenellenbogen BS. 2009. Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. Mol. Cell. Biol. 29:1749-1759.
55. Utku Y, et al. 2006. A peptidomimetic siRNA transfection reagent for highly effective gene silencing. Mol. Biosyst. 2:312-317.
56. Wang Y, et al. 2005. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679.
57. Willems AR, et al. 1999. SCF ubiquitin protein ligases and phosphorylation-dependent proteolysis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354: 1533-1550.
58. Willems AR, Schwab M, Tyers M. 2004. A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochim. Biophys. Acta 1695:133-170.
59. Zhao JJ, et al. 2008. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283:31079-31086.